> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Jazz Stock Soars 8%, Adding $1.1 Billion, After It Raises 2026 Revenue Forecast
- URL: https://www.bullished.co/jazz-stock-soars-8-adding-1-1-billion-after-it-raises-2026-revenue-forecast-e126f2f3/
- Published: 2026-11-03T15:21:49.000Z
- Updated: 2026-11-03T15:21:49.000Z
- Description: The drugmaker lifted its full-year sales outlook even as a $754 million acquired-research charge pushed the quarter to a loss.
- Author: Matteo Parrino
- Tags: Markets, JAZZ, Industry: Healthcare

[Jazz Pharmaceuticals](https://www.bullished.co/tag/jazz/), which makes medicines for sleep disorders, epilepsy and cancer, saw its shares [climb 7.72% to $230.99](https://finance.yahoo.com/markets/stocks/articles/jazz-pharmaceuticals-jazz-could-27-021510385.html?ref=bullished.co) in Tuesday trading, as of 10:20 a.m. ET, adding about $1.1 billion in market value. The rally followed Monday's [SEC filing](https://www.sec.gov/Archives/edgar/data/0001232524/000123252426000056/jazz-20261102.htm?ref=bullished.co), which raised the company's 2026 revenue outlook.

## Record sales, then a loss

Quarterly sales of [$1,243.0 million](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/jazz-20260930.htm?ref=bullished.co) rose 10%. A $754 million acquired-research charge tied to the Actio deal still left Jazz with a $483.4 million net loss.

The charge works out to $11.32 per share, the company reported, and it drove the quarter's loss.

On Monday's earnings call, management flagged that a rival small cell lung cancer drug launch will be a 2027 headwind for Jazz's own lung cancer drug.

## A pivot toward cancer drugs

Jazz sells Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for severe seizure disorders, and cancer drugs including Ziihera, Modeyso, Zepzelca and Rylaze. Xywav made up 41% of net product sales in 2025, followed by Epidiolex at 26%.

The company has been moving toward oncology through the Actio acquisition and the launch of Ziihera, while its older sleep franchise faces pressure.

## Biggest gain since February

The stock was on pace for its biggest one-day gain since Feb. 25, when it rose 13.2%. Shares were up about 26% for the year at Monday's close, against about 10% for the S&P 500.

Monday's call put the 2027 lung cancer launch from a rival on the table, even as the 2026 outlook went up.

### Sources

- [Jazz Pharmaceuticals (JAZZ) Could Be 27% Undervalued As Record Revenue Lifts Outlook](https://finance.yahoo.com/markets/stocks/articles/jazz-pharmaceuticals-jazz-could-27-021510385.html?ref=bullished.co) — Yahoo Finance
- [Does Earnings Beat Change The Bull Case For Jazz Pharmaceuticals Stock (JAZZ)?](https://finance.yahoo.com/healthcare/articles/does-earnings-beat-change-bull-002326449.html?ref=bullished.co) — Yahoo Finance
- [Jazz outlines $4.775B-$4.85B 2026 revenue guidance as Ziihera launch builds toward $3B-$5B peak sales potential (NASDAQ:JAZZ)](https://seekingalpha.com/news/4663066-jazz-outlines-4%5F775b-4%5F85b-2026-revenue-guidance-as-ziihera-launch-builds-toward-3b-5b-peak?ref=bullished.co) — seekingalpha.com
- [Jazz Pharmaceuticals (JAZZ) Stock Could Be Undervalued On Ziihera Launch News](https://sg.finance.yahoo.com/news/jazz-pharmaceuticals-jazz-stock-could-012206769.html?ref=bullished.co) — Yahoo Finance
- [Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates](https://finance.yahoo.com/healthcare/articles/jazz-pharmaceuticals-jazz-reports-q3-212503808.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [The company's filing (Jazz Pharmaceuticals)](https://www.sec.gov/Archives/edgar/data/0001232524/000123252426000056/jazz-20261102.htm?ref=bullished.co) — SEC filing
- [Jazz Pharmaceuticals — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/jazz-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Jazz Pharmaceuticals

- [Jazz Says Rival Lung Cancer Drug Will Be A 2027 Headwind For Zepzelca, Even As It Raises 2026 Outlook](https://www.bullished.co/jazz-says-rival-lung-cancer-drug-will-be-a-2027-headwind-for-zepzelca-even-as-it-raises-034006e5/)
- [Jazz Expensed $754.2 Million Of Its Actio Deal At Once, Turning Record Revenue Into A Loss](https://www.bullished.co/jazz-expensed-754-2-million-of-its-actio-deal-at-once-turning-record-revenue-into-a-loss-418829a7/)
- [Jazz Lifts 2026 Revenue Outlook To $4.775 Billion–$4.85 Billion Despite $754 Million Actio Charge](https://www.bullished.co/jazz-lifts-2026-revenue-outlook-to-4-775-billion-4-85-billion-despite-754-million-actio-f11069a0/)

[All Jazz Pharmaceuticals (JAZZ) coverage →](https://www.bullished.co/tag/jazz/)